Latest news with #LunitINSIGHTMMG
Korea Herald
19-05-2025
- Business
- Korea Herald
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX: a leading provider of AI for cancer diagnostics and therapeutics, today announced major milestones in the United States, one year after its acquisition of Volpara Health Technologies. Since acquiring Volpara, Lunit has significantly expanded its presence across North America. By June 2025, Lunit's AI solutions for digital breast tomosynthesis (Lunit INSIGHT DBT) and mammography analysis (Lunit INSIGHT MMG) will be deployed at over 200 imaging centers and hospitals across the U.S., with approximately 350 to 400 radiologists utilizing its technology. Together, Lunit and Volpara now power more than one million annual mammograms across North America — a major step forward in the company's U.S. growth strategy. Lunit's growing customer base includes leading healthcare providers such as Rezolut, SimonMed Imaging, and UC Davis Health, reflecting its strengthening position in the U.S. medical imaging market. In addition to its expanding U.S. footprint, Lunit and Volpara introduced the concept of a comprehensive Ecosystem for Cancer Detection and Care at RSNA 2024. The Ecosystem is designed to unify AI technologies for lesion detection, workflow optimization, quality control, and patient engagement—empowering clinicians with actionable insights and scalable solutions across the cancer care continuum. Lunit and Volpara also demonstrated the complementary value of combining Lunit INSIGHT Risk and Volpara Risk Pathways at RSNA 2024—offering a glimpse into how imaging-based and clinical data may be used together to personalize breast cancer risk assessment. The two solutions were shown as a prototype to work in tandem, that would predict the likelihood of breast cancer development within 1 to 5 years, to enable earlier interventions, more personalized care, and redefine standards for breast cancer screening and management. "The successful integration of Lunit and Volpara has accelerated our mission to transform cancer diagnostics globally, and the momentum we've built in the United States marks just the beginning," said Brandon Suh, CEO of Lunit. "By combining Lunit's AI innovation with Volpara's breast health expertise, we're delivering a new standard of comprehensive support for clinicians—enhancing early detection, improving screening quality, optimizing workflows, and ultimately helping providers deliver better outcomes for patients worldwide. With our expanded footprint and comprehensive ecosystem, we are poised to lead the future of cancer care." Lunit plans to further expand its U.S. operations, building on its strong foundation with next-generation AI solutions, dedicated clinical support, and a growing ecosystem designed to shape the future of cancer detection and care. Founded in 2013, Lunit (KRX: is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology —and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at
Korea Herald
07-05-2025
- Business
- Korea Herald
Lunit to Power Germany's Largest Private Radiology Network with AI Imaging
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX: a leading provider of AI for cancer diagnostics and therapeutics, today announced a strategic partnership with Starvision Service GmbH, Germany's largest private radiology network. Through a newly signed framework agreement, Lunit's AI imaging solutions will be deployed across Starvision's expansive network of radiological practices. Starvision operates 79 locations across seven German federal states, delivering services in radiology, nuclear medicine, and radiation therapy. As a recognized leader in the DACH healthcare market, Starvision is known for its commitment to digital transformation, operational excellence, and high-quality patient care. Under the agreement, Starvision will adopt several of Lunit's AI solutions, including: The first commercial deployments are already underway—including use of Lunit INSIGHT MMG at Radiologische Allianz in Hamburg, supporting the Hamburg breast cancer screening program under the Starvision network. Together with deployments at Die Radiologie, a major regional hospital group operating over 20 medical sites across Bavaria, Lunit's solutions are now supporting approximately 120,000 breast cancer screenings and diagnoses annually across the two institutions. The five-year framework agreement allows additional Starvision locations—and newly affiliated practices—to join at any time, enabling broad scalability across the network. New deployments and clinical trials are already in progress, with individual agreements being signed across Starvision's entities as part of a phased implementation plan. Beyond Starvision, several other healthcare providers across Germany have also expressed interest, reflecting the expanding demand for AI-driven imaging solutions. "Lunit's AI solutions support our radiologists in delivering fast and accurate diagnoses. This strengthens diagnostic confidence and gives us more time to focus on what truly matters: the individual care of our patients," said Uwe Pfeifer, CEO of Starvision Service GmbH. "Partnering with Starvision accelerates our vision of bringing AI-powered precision diagnostics into everyday clinical practice," said Brandon Suh, CEO of Lunit. "Together, we are advancing a new era of radiology where technology enhances the expertise of physicians, delivering better outcomes for millions of patients in Germany and beyond." The partnership supports both companies' vision of transforming healthcare through intelligent technology and setting new standards in radiology. About Lunit Founded in 2013, Lunit (KRX: is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology —and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at
Yahoo
10-03-2025
- Health
- Yahoo
World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection
Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings without raising recall rates, presenting a game-changing tool for countries relying on single-reader mammography screening SEOUL, South Korea, March 10, 2025 /PRNewswire/ -- Lunit (KRX: a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a groundbreaking prospective study in Nature Communications validating the real-world effectiveness of AI-powered mammography screening in South Korea's national breast cancer screening program. Conducted as the world's first large-scale, multicenter prospective study in a single-reading setting, the research underscores how AI-assisted mammography interpretation significantly improves breast cancer detection rates without increasing recall rates. The study was led by Professor Yun-Woo Chang from Soonchunhyang University Seoul Hospital, in collaboration with both breast and general radiologists from six leading academic hospitals in South Korea. The study analyzed 24,543 women aged 40 and above who underwent routine biennial mammography (2D full-field digital mammogram) between February 2021 and December 2022 as part of Korea's national breast cancer screening program. The study compared the performance of breast radiologists interpreting screening mammograms with and without Lunit's AI-based computer-aided detection, Lunit INSIGHT MMG. The results revealed that AI-assisted breast radiologists detected 13.8% more screen-detected breast cancers than those relying solely on conventional interpretation methods, or without AI assistance. The cancer detection rate (CDR) increased from 5.01 (per 1,000) to 5.70 with AI assistance, while recall rates (RRs) remained statistically unchanged, ensuring improved clinical effectiveness and minimizing unnecessary additional recalls. Moreover, AI assistance led to a significant improvement in detecting small-sized tumors and node-negative cancers, key indicators of improved early detection. Additionally, the study evaluated Lunit INSIGHT MMG's impact on general radiologists who do not specialize in breast imaging through a simulated retrospective study. The results demonstrated that AI assistance led to an even greater improvement in CDRs for general radiologists, with an increase of 26.4% (3.87 to 4.89 per 1,000), underscoring AI's potential to support radiologists with varying levels of expertise. "This prospective study offers compelling real-world evidence that AI can improve early cancer detection while maintaining effectiveness and reducing unnecessary patient anxiety caused by false positives in a single-reading setting," said Professor Chang, the lead and corresponding author of the study. A Proven Solution for Single and Double-Reading Screening Systems The publication further builds upon Lunit INSIGHT MMG's well-established track record in improving breast cancer detection. In Sweden, Capio St. Göran Hospital conducted a prospective clinical trial to assess Lunit AI's effectiveness in breast cancer screening when replacing one reader within a double-reading setting. Following positive trial results, Capio St. Göran Hospital became the world's first to replace one of two radiologists in its double-reading workflow with AI, marking a paradigm shift in breast cancer screening. "This latest prospective study in South Korea further solidifies Lunit INSIGHT MMG's potential as an indispensable tool in breast cancer screening," said Brandon Suh, CEO of Lunit. "Whether in a single-reader or double-reader setting, AI can serve as a powerful force multiplier, assisting radiologists in detecting cancer earlier and more accurately." Shaping the Future of National Breast Cancer Screening Programs With mounting evidence supporting AI's role in breast cancer screening, Lunit is driving its global adoption. Lunit INSIGHT MMG has already been deployed in national breast screening programs in Australia, Sweden, Iceland, Singapore, Saudi Arabia, and Qatar, helping healthcare systems enhance efficiency and optimize diagnostic accuracy. The study's findings are expected to influence global breast cancer screening protocols, particularly in countries where single-reading mammography interpretation is widely practiced. By demonstrating AI's ability to enhance radiologists' accuracy without increasing RRs, the study provides critical data supporting AI's role in optimizing cancer detection while reducing the workload burden on radiologists. This is particularly relevant as many countries face a shortage of specialized breast imaging professionals, making AI an important tool to improve efficiency and maintain high diagnostic standards. "As AI adoption accelerates, we remain committed to driving innovation and making AI-powered cancer screening the new standard of care," added Suh. "By working closely with healthcare providers worldwide, we aim to ensure that AI benefits as many patients as possible." About Lunit Founded in 2013, Lunit (KRX: is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at View original content to download multimedia: SOURCE Lunit
